Print full article

Boehringer invests $50M in Puerto Rico facility

The plant’s expansion allows for the manufacturing of afoxolaner

Suggested Veterinary Products

Boehringer Ingelheim has expanded the production capacity of its manufacturing site in Barceloneta, P.R., with a $50-million investment.

The expansion allows the facility to start producing the company’s brand of afoxolaner, a flea and tick preventive that is U.S. Food and Drug Administration- (FDA-) approved. The site already packages the product, which is manufactured in Brazil, for shipment to the U.S. and Canada.

“Our site in Puerto Rico is critical to meet growing demand for products that help protect pets from disease,” says Everett Hoekstra, president of Boehringer Ingelheim Animal Health USA.

The investment will create up to 105 full-time jobs at the plant in the next three to five years, bringing employment at the site to more than 320.

The plant, which has been operational for 48 years, currently manufactures the company’s ivermectin/pyrantel heartworm preventive.

Leave a Comment



Sign-up for your account with Veterinary Practice News. Your account gives you unlimited free access to our Newsletter Archives and our Digital Editions of Veterinary Practice News.
Please check the box below to confirm you would like to be added to Kenilworth Media’s various e-mail communications (includes e-newsletters, a survey now and then, and offers to the veterinarian industry*).

Leave this empty:

*We do not sell your e-mail address to 3rd parties, we simply forward their offers to you. Of course, you always have the right to unsubscribe from any communications you receive from us, should you change your mind in the future.